Program Overview
The Congressionally Directed Medical Research Programs (CDMRP) exists to move high-impact biomedical research forward in areas that matter to Service Members, their families, Veterans, and the broader public, often where traditional funding pathways may not fully cover the risk or urgency. In FY26, that mission is paired with one of CDMRP’s defining advantages: a two-tier review designed to balance scientific excellence with programmatic relevance, using peer review plus a programmatic review that aligns awards to the program’s goals.
FY26 appropriations restore CDMRP to $1.27 billion
On February 3, 2026, CDMRP received $1.27B in appropriations for 34 research programs, a major restoration of capacity and breadth across disease areas and warfighter-relevant needs.
That is a dramatic shift from FY25, when the “Full-Year Continuing Appropriations and Extensions Act of 2025” provided $650M and funding concentrated into a much smaller set of programs.
If you have been waiting for CDMRP to “open back up,” this is that moment.
What is funded in FY26
The FY26 portfolio spans 34 programs, but a few anchors carry a meaningful share of the total.
High-level highlights worth knowing early:
- Peer Reviewed Medical Research Program (PRMRP): $370M (52 topics)
- Peer Reviewed Cancer Research Program (PRCRP): $165M (20 topics)
- Breast Cancer: $145M
- Prostate Cancer: $75M
- Ovarian Cancer: $50M
- Multiple additional programs at meaningful levels, including melanoma, ALS, TBI and psychological health, spinal cord injury, toxic exposures, lupus, kidney cancer, lung cancer, and more.
The practical takeaway: even if your work is not a perfect fit for a single disease program, PRMRP and PRCRP are often the broadest entry points because they fund multiple topic areas within one umbrella.
What happens next: pre-announcements, then FOAs
CDMRP will roll out pre-announcements and then full Funding Opportunity Announcements (FOAs) as each program finalizes mechanisms, intent, and timelines. FOAs will be posted on CDMRP, Grants.gov, and eBRAP, and CDMRP explicitly notes that applications must conform to the final FOA posted on Grants.gov.
Two actions I recommend doing now:
- Reach out to your Grant Engine Program Manager
- Subscribe to our newsletter for additional news releases
How to navigate CDMRP opportunities efficiently
A clean workflow that saves weeks:
- Start from the program list, not from Grants.gov
Grants.gov is necessary, but CDMRP program pages and pre-announcements are often the fastest way to understand fit and mechanism intent early. - Anchor on mechanism intent and review criteria
CDMRP tailors review criteria by mechanism, and your job is to write to those criteria, not to a generic NIH template. - Plan for eBRAP pre-application as a gating step
CDMRP requires a pre-application in eBRAP for all funding opportunities (often a Letter of Intent or a Pre-Proposal). If you wait until the FOA drops to operationalize eBRAP and your internal assets, you will feel behind immediately.
Strategies for success in FY26
Here is what consistently de-risks the effort and raises win probability:
- Write for the warfighter and those who support them: make relevance explicit, specific, and measurable.
- Treat the two-tier review as two different audiences: scientific peer reviewers need rigor and feasibility; programmatic reviewers need portfolio-fit, impact, and relevance to program goals.
- Lead with a “why now” gap: show the research or translational gap CDMRP is uniquely positioned to bridge.
- Make feasibility unavoidable: powered studies, credible models, access to samples or subjects (if applicable), and a realistic plan.
The “military champion” concept, done correctly
Having a real end-user advocate is often decisive, but it should be structured as mission pull, not name-dropping. The best versions look like:
- A military or VA collaborator who helps define the operational problem and validates requirements
- Letters of support that speak to adoption, deployment constraints, and why your solution matters now
- A study design that reflects real-world use, not just lab success
With CDMRP back to $1.27B in FY26, the opportunity set is meaningfully broader, and the time to position is before mechanisms fully hit the street.
Need help securing significant funding? If you have questions about how these updates affect your strategy, or want support preparing for finding new opportunities, contact us. Together, we will continue pushing innovation forward.
Text: (650) 885-9872
Email: greatscience@grantengine.com
Website: grantengine.com
Additional Resources:
- CDMRP Website: https://cdmrp.health.mil
- Upcoming Funding Opportunities: https://cdmrp.
health.mil/pubs/press/press - To subscribe to opportunities: https://ebrap.org/eBRAP/
programSubscription/Subscribe. htm